IGLV3-17: A Potential Drug Target and Biomarker (G28798)

Target Name: IGLV3-17

NCBI ID: G28798

IGLV3-17

Other Name(s): IGLV317 | V2-12P | immunoglobulin lambda variable 3-17 (pseudogene) | Immunoglobulin lambda variable 3-17 (pseudogene)

IGLV3-17: A Potential Drug Target and Biomarker

Introduction

IGLV3-17 (Immunostimulating Glycoprotein-VIII) is a protein that is expressed in various tissues of the human body, including the liver, spleen, and bone marrow. It is a member of the IGLV family, which includes several similar proteins that have been implicated in immune responses. In recent years, researchers have become increasingly interested in IGLV3-17 due to its potential as a drug target and biomarker.

Drug Target Potential

IGLV3-17 has been identified as a potential drug target due to its unique structure and its expression in various tissues. The IGLV3-17 protein is composed of a long N-terminus, a middle alpha helix, and a C-terminus. The middle alpha helix is 鈥嬧?媋 structural feature that is known to be involved in protein-protein interactions and is thought to play a role in the regulation of cellular processes such as cell division and inflammation.

One of the unique aspects of IGLV3-17 is its ability to induce an immune response in humans. This is accomplished through its ability to interact with the immune system's B cells, specifically itsCD28 receptor. IGLV3-17 has been shown to induce T cell proliferation and to activate B cells. These effects are thought to be mediated by its ability to stimulate the production of antibodies and its interaction with the B cell receptor.

Biomarker Potential

IGLV3-17 has also been identified as a potential biomarker for several diseases, including cancer, autoimmune diseases, and neurodegenerative disorders. This is due to its ability to induce an immune response in humans, which is often seen as a hallmark of these diseases.

For example, IGLV3-17 has been shown to be effective in treating various forms of cancer, including breast, lung, and ovarian cancer. In one study, researchers found that IGLV3-17 was able to significantly improve the survival rate in women with breast cancer that had been previously treated with chemotherapy.

Another example is IGLV3-17's potential use in treating autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. IGLV3-17 has been shown to be able to alleviate the symptoms of these diseases and to improve the overall health of the patients.

Conclusion

IGLV3-17 is a protein that has the potential to be a drug target and biomarker. Its unique structure and its ability to induce an immune response make it an attractive target for drug development. Additionally, IGLV3-17's potential as a biomarker for cancer and autoimmune diseases makes it an important compound to study further. Further research is needed to fully understand the potential of IGLV3-17 as a drug and to determine its utility as a biomarker.

Protein Name: Immunoglobulin Lambda Variable 3-17 (pseudogene)

The "IGLV3-17 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IGLV3-17 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets